Abeona Therapeutics’ (ABEO) Buy Rating Reiterated at HC Wainwright

Abeona Therapeutics (NASDAQ:ABEO)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued on Monday, Marketbeat.com reports. They currently have a $15.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 200.00% from the company’s previous close. HC Wainwright also issued estimates for Abeona Therapeutics’ Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.05 EPS and FY2026 earnings at ($0.12) EPS.

Several other analysts have also recently commented on the company. StockNews.com cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 22nd. Oppenheimer assumed coverage on Abeona Therapeutics in a research note on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 price objective for the company. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $17.50.

Abeona Therapeutics Stock Performance

Shares of ABEO opened at $5.00 on Monday. The company has a 50-day moving average of $5.43 and a two-hundred day moving average of $5.82. The stock has a market cap of $217.36 million, a price-to-earnings ratio of -1.86 and a beta of 1.79. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. Abeona Therapeutics has a one year low of $3.05 and a one year high of $8.45.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.19. On average, equities research analysts expect that Abeona Therapeutics will post -1.16 earnings per share for the current year.

Hedge Funds Weigh In On Abeona Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of ABEO. Twinbeech Capital LP acquired a new position in shares of Abeona Therapeutics in the fourth quarter worth $58,000. Squarepoint Ops LLC purchased a new position in Abeona Therapeutics in the fourth quarter valued at about $67,000. Jane Street Group LLC acquired a new position in Abeona Therapeutics in the 3rd quarter worth about $84,000. Oxford Asset Management LLP acquired a new position in Abeona Therapeutics in the 4th quarter worth about $118,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in shares of Abeona Therapeutics during the 3rd quarter worth about $151,000. 80.56% of the stock is currently owned by hedge funds and other institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.